Patients Divided Over Alzheimerās Drug: Is It a āRisk Iām Willing to Takeā or Just a āMagic Pillā?
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimerās disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.